50 / 62
Ongoing IO studies in 2L+
PEMBROLIZUMAB
•
NCT02963090
(ph2):
Pembrolizumab vs
Topotecan
•
MISP-MK3475
(ph2): Paclitaxel +
Pembrolizumab
Pembrolizumab as
maintenance
ATEZOLIZUMAB
•
NCT03059667
(ph2): Atezolizumab
+ CT vs CT
(Topotecan or EC
rechallenge)
DURVALUMAB
•
NCT02701400(ph2): RT +
Tremelimumab +
Durvalumab vs Treme +
Durvalumab
•
BALTIC/NCT02937818(ph
2): Durva+Treme vs
AZD1775 + Carboplatin
•
MEDIOLA (ph1/2):
Olaparib + Durvalumab
Clinicaltrial.gov